Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787656 · ClinicalTrials.gov registry record
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
A clinical trial, sponsored by University of South Alabama.
- Completed
- Registry status
- 438
- Enrollment target
NCT01787656: Completed study, sponsored by University of South Alabama.
NCT01787656 is a clinical trial that has completed, run by University of South Alabama. The registered enrollment target is 438 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01787656 has completed, sponsored by University of South Alabama.
- COMPLETED
- Registry status
- 438 participants
- Enrollment target
Study Summary
Ovarian cancer is deadly and generally diagnosed at late stage when the chances of survival are low. There is a current belief that this cancer starts in the fallopian tubes and progresses towards the ovaries, spreading to the cells on the surface. Within the fallopian tubes and the uterus, there is a constant flow of mucus which has only one exit through the cervix and out the vagina. Proteins that are generated within the entire female reproductive system are trapped into this viscous fluid and eventually released as waste. When a routine PAP test is performed, a sample of this mucus is collected along with any cells, and preserved in the PAP fluid. The fluid is currently discarded but contains a protein profile showing of the status of the cells in the female reproductive system. We have examined this fluid and found that it contains unique peptides/proteins that provide a diagnosis of ovarian cancer when compared against healthy controls. These markers will be initially refined using the comparison of ovarian cancer patients against those with benign adnexal masses that entered the clinic during the same time period. In this Phase II biomarker validation study we will further refine and validate these biomarkers using a new collection of samples from at least 200 ovarian cancer cases with epithelial ovarian cancer (endometroid and papillary serous histology, most common) and comparing these against 600 patients with a diagnosis of a benign adnexal mass that enter the clinics during the same time period. Patient samples will be collected on their first visit to the gynecologic oncologist at a number of collaborating clinics. Final processing of all of the samples will be performed within the proteomics research facilities of the Mitchell Cancer Institute using Selected Reaction Monitoring (SRM, with mass spectrometry) based on the refined set of makers statistically selected within the first aim. Biomarkers validated within this study will be compared with the w
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2013-01 |
| Est. Completion | 2018-08 |
What the finished NCT01787656 record still lists
NCT01787656 is an observational study that tracks outcomes without assigning an intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01787656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01787656 about?
NCT01787656 is a clinical study titled "A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus". Ovarian cancer is deadly and generally diagnosed at late stage when the chances of survival are low. There is a current belief that this cancer starts in the fallopian tubes and progresses towards the ovaries, spreading to the cells on the surface. Within the fallopian tubes and the uterus, there is...
What is the current status of trial NCT01787656?
This trial is currently completed. The enrollment target is 438 participants. The study started on 2013-01. Estimated completion is 2018-08.
Who is sponsoring clinical trial NCT01787656?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia